cancer;
infection;
microbiome;
cancer dysbiosis;
tumor microbiome;
cancer therapy response;
EPSTEIN-BARR-VIRUS;
INVASIVE FUNGAL-INFECTIONS;
NON-HODGKINS-LYMPHOMA;
PANCREATIC-CANCER;
HELICOBACTER-PYLORI;
GUT MICROBIOTA;
GASTRIC-CANCER;
TRANSPLANT RECIPIENTS;
COLORECTAL-CANCER;
CURRENT KNOWLEDGE;
D O I:
10.3390/ijms21093115
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Cancer is one of the most aggressive and deadly diseases in the world, representing the second leading cause of death. It is a multifactorial disease, in which genetic alterations play a key role, but several environmental factors also contribute to its development and progression. Infections induced by certain viruses, bacteria, fungi and parasites constitute risk factors for cancer, being chronic infection associated to the development of certain types of cancer. On the other hand, susceptibility to infectious diseases is higher in cancer patients. The state of the host immune system plays a crucial role in the susceptibility to both infection and cancer. Importantly, immunosuppressive cancer treatments increase the risk of infection, by decreasing the host defenses. Furthermore, alterations in the host microbiota is also a key factor in the susceptibility to develop cancer. More recently, the identification of a tumor microbiota, in which bacteria establish a symbiotic relationship with cancer cells, opened a new area of research. There is evidence demonstrating that the interaction between bacteria and cancer cells can modulate the anticancer drug response and toxicity. The present review focuses on the interaction between microbes and cancer, specifically aiming to: (1) review the main infectious agents associated with development of cancer and the role of microbiota in cancer susceptibility; (2) highlight the higher vulnerability of cancer patients to acquire infectious diseases; (3) document the relationship between cancer cells and tissue microbiota; (4) describe the role of intratumoral bacteria in the response and toxicity to cancer therapy.
机构:
Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
Univ N Carolina, Ctr GI Biol & Dis, Chapel Hill, NC 27599 USAUniv N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
Uronis, J. M.
Jobin, C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USAUniv N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
机构:
Broad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USABroad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA
Kostic, Aleksandar D.
Chun, Eunyoung
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USABroad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA
Chun, Eunyoung
Meyerson, Matthew
论文数: 0引用数: 0
h-index: 0
机构:
Broad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA
Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA
Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USABroad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA
Meyerson, Matthew
Garrett, Wendy S.
论文数: 0引用数: 0
h-index: 0
机构:
Broad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA
Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USA
Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA
Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USABroad Inst Harvard & MIT, Canc Program & Infect Dis Initiat, Cambridge, MA USA